Investigation in Progress — No Complaint Filed Yet

BG&G is actively investigating potential securities fraud claims against Foghorn Therapeutics Inc.. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.

About This Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of shareholders of Foghorn Therapeutics Inc. (NASDAQ: FHTX).

On October 1, 2026, Foghorn Therapeutics Inc. announced that, following a review of clinical data from the Phase 1 dose-escalation trial of FHD-909 (LY4050784), the Company and its collaboration partner, Eli Lilly, decided not to advance the program into the clinical development expansion phase. The companies also decided to discontinue development of their Selective SMARCA2 degrader program and indicated that they did not anticipate further collaboration activities. As a result, Foghorn stated that it would prioritize resources toward its proprietary portfolio programs. Following this news, Foghorn’s stock price declined more than 30.8% on October 2, 2026.

What We Are Investigating

  • Whether Foghorn Therapeutics Inc. and certain of its officers made false or misleading statements regarding the Company's financial condition and business prospects.
  • Whether Foghorn Therapeutics Inc. failed to disclose material adverse information that would have been significant to a reasonable investor.
  • Whether the Company's earnings guidance was supported by a reasonable factual basis at the time it was made.

What Investors Should Do

If you purchased or acquired FHTX securities and suffered a loss, you may have a claim.
Contact BG&G to share relevant facts or information about your purchase.
There is no cost or obligation — our firm works exclusively on a contingency fee basis.
You do not need to have sold your shares to contact us.

FHTX — Stock Performance

About Bronstein, Gewirtz & Grossman, LLC

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

We handle cases on a contingency fee basis — we advance all litigation costs on your behalf. There is no fee unless we are successful.

“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”
— Peretz Bronstein, Founding Partner